Who We Are

The ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell and Gene Therapy is composed of prominent experts in the cell and gene therapy field. Their leadership spans academia, industry, and regulation. The Task Force strives to characterize unproven and unethical cell and gene interventions, and promote safe and effective practices worldwide.

Learn more about the Task Force – Click here to view  

 News

January 2019	FDA issues press release on reported safety concerns with Genetech, Inc umbilical cord blood-derived products. ’12 People Hospitalized with Infections from Stem Cell Shots’ – The New York Times ‘FDA Cracks Down on Purveyors of Stem Cell Treatments’ – The Scientist
November 2018	ISCT publishes annual report on cell and gene therapy  market authorizations
June 2018	Speakers from ISCT’s 2018 Annual Meeting Presidential Task Force Session on UCTs referenced in The Medicine Maker: Peter Marks, Massimo Dominici
June 20, 2018	ISCT Presidential Task Force on UCT Committee Members publish in Lancet Respiratory Medicine:  Leigh Turner, Dan Weiss, Laertis Ikonomou
August 30, 2017	ISCT Response to Aug 28th FDA Statement Concerning Regulatory Oversight of Cellular Therapies
August 28, 2017	US FDA Commissioner Scott Gottlieb, M.D., issues statement on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine
July 7, 2017	Global interest in report co-authored by members of ISCT Presidential Task Force on UCT
December 2, 2016	ISCT Publishes Article in Translational Scientist Concerning the US REGROW Act
October 19, 2016	ISCT Presidential Task Force Publishes Article in Brain Circulation Journal